Skip to main content
Fig. 7 | Respiratory Research

Fig. 7

From: Serum metabolomic signatures of fatty acid oxidation defects differentiate host-response subphenotypes of acute respiratory distress syndrome

Fig. 7

Increased 3-methylhistidine and octanoylcarnitine levels are associated with 30-day mortality and vasopressor use in patients with acute respiratory failure. The cohort includes airway controls, Class 1, and Class 2 ARDS patients and was stratified by 30-day survival (a–c) and vasopressor use within 7 days of study enrollment (d–f). a Relative acetylcarnitine levels are shown for survivors (N = 111) and non-survivors (N = 39). b Relative octanoylcarnitine levels are shown for survivors (N = 98) and non-survivors (N = 32). c Relative 3-methylhistidine levels are shown for survivors (N = 111) and non-survivors (N = 39). d Relative acetylcarnitine levels are shown for patients not on vasopressors (N = 72) and those requiring vasopressors (N = 78). e Relative octanoylcarnitine levels are shown for patients not on vasopressors (N = 60) and those requiring vasopressors (N = 70). f Relative 3-methylhistidine levels are shown for patients not on vasopressors (N = 72) and those requiring vasopressors (N = 78). Statistical analysis was performed using the Mann–Whitney U test with P-values shown

Back to article page